342 filings
Page 7 of 18
8-K
fx2 knt05uzs5iwoxup5
23 Jun 11
Departure of Directors or Certain Officers
12:00am
8-K
kpzwrcffz5zrb9ekoa5
6 Jun 11
Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
12:00am
8-K
8t4ps9i7
3 Jun 11
ARIAD Announces Initial Clinical Data on Ponatinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia
12:00am
8-K
xhisdfnfy2m8
6 May 11
ARIAD Reports First Quarter 2011 Financial Results and Development Progress
12:00am
8-K
e8u 72644bifqqo
2 May 11
ARIAD Names Norbert Riedel to Its Board of Directors
12:00am
8-K
7k7adhc1jvqucv95z
21 Apr 11
ARIAD Announces Three Exclusive Out-License Agreements to Develop and Commercialize Its ARGENT™ Cell-Signaling Regulation Technology
12:00am
8-K
ag7v kyvjl
28 Mar 11
ARIAD And MolecularMD Announce Collaboration for a Companion Diagnostic Test for The T315I BCR-ABL Mutation in Patients With CML
12:00am
8-K
1hccp
18 Mar 11
ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval
12:00am
8-K
9na5fl97ae9jvg 5o4jc
17 Feb 11
ARIAD Reports Development Progress and Fourth Quarter and Year-End 2010 Financial Results
12:00am
8-K
tztvigitibqtooc6
19 Jan 11
Other Events
12:00am
8-K
wjbb7jrgg0wt
12 Jan 11
Entry into a Material Definitive Agreement
12:00am
8-K
l72pqz
7 Dec 10
ARIAD’s Ponatinib Shows Clinical Evidence of Improving Anti-Leukemic Activity in Patients with Drug-Resistant CML
12:00am
8-K
wrlxmak350 btw
9 Nov 10
ARIAD Reports Third Quarter 2010 Financial Results and Development Progress
12:00am
8-K
lz22e54tf08 8bu7jnxo
27 Oct 10
Entry into a Material Definitive Agreement
12:00am
8-K
rlbsq45na95agam
25 Oct 10
ARIAD Announces Interim Results from Randomized Phase 2 Trial of Oral Ridaforolimus in Advanced Endometrial Cancer
12:00am
8-K
ctpwkazyoerp86b
13 Sep 10
ARIAD Announces Initiation of Ponatinib (AP24534) Pivotal Trial in Drug-Resistant or Intolerant Chronic Myeloid Leukemia
12:00am
8-K
xnl6i1yrxsf
4 Aug 10
ARIAD Reports Second Quarter 2010 Financial Results and Development Progress
12:00am
8-K
dvmlymrwq0195fdhq
25 Jun 10
ARIAD Names Timothy P. Clackson to New Position of President of Research and Development
12:00am
8-K
kp0 uxiuvj3jbn
7 Jun 10
ARIAD Presents Updated Clinical Data on Its Investigational Pan-BCR-ABL Inhibitor, AP24534, in Drug-Resistant Chronic Myeloid Leukemia
12:00am
8-K
c8ejejyu388d4al ya
25 May 10
Other Events
12:00am